In vivo approach for the evaluation of mechanism-based inhibition of cytochrome P450 3A in rats

References

• Chovan JP, Ring SC, Yu E, Baldino JP. Cytochrome P450 probe substrate metabolism kinetics in Sprague–Dawley rats. Xenobiotica 2007; 37(5)459–473
   PubMed Web of Science ®Google Scholar
• Danan G, Descatoire V, Pessayre D. Self-induction by erythromycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450. Journal of Pharmacology and Experimental Therapeutics 1981; 218(2)509–514
   PubMedGoogle Scholar
• Desgranges C, Razaka G, De Clercq E, Herdewijn P, Balzarini J, Drouillet F, Bricaud H. Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. Cancer Research 1986; 46(3)1094–1101
   PubMed Web of Science ®Google Scholar
• Ghosal A, Satoh H, Thomas PE, Bush E, Moore D. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metabolism and Disposition 1996; 24(9)940–947
   PubMed Web of Science ®Google Scholar
• He K, Woolf TF, Hollenberg PF. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486). Journal of Pharmacology and Experimental Therapeutics 1999; 288(2)791–797
   PubMed Web of Science ®Google Scholar
• Imaoka S, Terano Y, Funae Y. Changes in the amount of cytochrome P450s in rat hepatic microsomes with starvation. Archives of Biochemistry and Biophysics 1990; 278(1)168–178
   PubMed Web of Science ®Google Scholar
• Ishigami M, Kawabata K, Takasaki W, Ikeda T, Komai T, Ito K, Sugiyama Y. Drug interaction between simvastatin and itraconazole in male and female rats. Drug Metabolism and Disposition 2001; 29(7)1068–1072
   PubMedGoogle Scholar
• Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. Prediction of pharmacokinetic alterations caused by drug–drug interactions: metabolic interaction in the liver. Pharmacological Reviews 1998; 50(3)387–412
   PubMed Web of Science ®Google Scholar
• Ito K, Ogihara K, Kanamitsu S, Itoh T. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metabolism and Disposition 2003; 31(7)945–954
   PubMedGoogle Scholar
• Kanazu T, Yamaguchi Y, Okamura N, Baba T, Koike M. Model for the drug–drug interaction responsible for CYP3A enzyme inhibition. I: Evaluation of cynomolgus monkeys as surrogates for humans. Xenobiotica 2004a; 34(5)391–402
   PubMed Web of Science ®Google Scholar
• Kanazu T, Yamaguchi Y, Okamura N, Baba T, Koike M. Model for the drug–drug interaction responsible for CYP3A enzyme inhibition. II: Establishment and evaluation of dexamethasone-pretreated female rats. Xenobiotica 2004b; 34(5)403–413
   PubMed Web of Science ®Google Scholar
• Kenny JR, Grime K. Pharmacokinetic consequences of time-dependent inhibition using the isolated perfused rat liver model. Xenobiotica 2006; 36(5)351–365
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Urashima K, Shimada N, Chiba K. Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat. Biochemical Pharmacology 2002; 63(5)889–896
   PubMed Web of Science ®Google Scholar
• Kose N, Yamamoto K, Sai Y, Isawa M, Suwa T, Nakashima E. Prediction of theophylline clearance in CCl4-treated rats using in vivo CYP1A2 and CYP3A2 contents assessed with the PKCYP test. Drug Metabolism and Pharmacokinetics 2005; 20(3)168–176
   PubMedGoogle Scholar
• Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Molecular Pharmacology 1989; 36(1)89–96
   PubMed Web of Science ®Google Scholar
• Lin HL, Kent UM, Hollenberg PF. Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein. Journal of Pharmacology and Experimental Therapeutics 2002; 301(1)160–167
   PubMed Web of Science ®Google Scholar
• Ma B, Prueksaritanont T, Lin JH. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metabolism and Disposition 2000; 28(2)125–130
   PubMed Web of Science ®Google Scholar
• Mayhew BS, Jones DR, Hall SD. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metabolism and Disposition 2000; 28(9)1031–1037
   PubMed Web of Science ®Google Scholar
• Miller VP, Stresser DM, Blanchard AP, Turner S, Crespi CL. Fluorometric high-throughput screening for inhibitors of cytochrome P450. Annals of the New York Academy of Sciences 2000; 919: 26–32
   PubMedGoogle Scholar
• Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR, Jr. Torsades de pointes occurring in association with terfenadine use. Journal of the American Medical Association 1990; 264(21)2788–2790
   PubMed Web of Science ®Google Scholar
• Mullins ME, Horowitz BZ, Linden DH, Smith GW, Norton RL, Stump J. Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers. Journal of the American Medical Association 1998; 280(2)157–158
   Web of Science ®Google Scholar
• Pharmaceutical Affairs Bureau, Japanese Ministry of Health and Welfare. A report on investigation of side effects of sorivudine 1994, deaths caused by interactions between sorivudine and 5-FU prodrugs (Tokyo: Pharmaceutical Affairs Bureau, Japanese Ministry of Health and Welfare). [in Japanese]
   Google Scholar
• Prueksaritanont T, Gorham LM, Ma B, Liu L, Yu X, Zhao JJ, Slaughter DE, Arison BH, Vyas KP. In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metabolism and Disposition 1997; 25(10)1191–1199
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Kuo Y, Tang C, Li C, Qiu Y, Lu B, Strong-Basalyga K, Richards K, Carr B, Lin JH. In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: A preclinical approach for CYP3A-mediated drug interaction studies. Drug Metabolism and Disposition 2006; 34(9)1546–1555
   PubMedGoogle Scholar
• Prueksaritanont T, Ma B, Tang C, Meng Y, Assang C, Lu P, Reider PJ, Lin JH, Baillie TA. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations. British Journal of Clinical Pharmacology 1999; 47(3)291–298
   PubMedGoogle Scholar
• Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics 1994; 270(1)414–423
   PubMed Web of Science ®Google Scholar
• Spatzenegger M, Jaeger W. Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metabolism Reviews 1995; 27(3)397–417
   PubMed Web of Science ®Google Scholar
• Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annual Review of Pharmacology and Toxicology 1998; 38: 389–430
   PubMed Web of Science ®Google Scholar
• Food US. Drug Administration, n.d. Website (Rockville, MD: US Food and Drug Administration) (available at: http://www.fda.gov/)
   Google Scholar
• Venkatakrishnan K, Obach RS. Drug–drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation. Current Drug Metabolism 2007; 8(5)449–462
   PubMedGoogle Scholar
• Venkatakrishnan K, Von Moltke LL, Obach RS, Greenblatt DJ. Drug metabolism and drug interactions: application and clinical value of in vitro models. Current Drug Metabolism 2003; 4(5)423–459
   PubMed Web of Science ®Google Scholar
• Watanabe A, Nakamura K, Okudaira N, Okazaki O, Sudo K. Risk assessment for drug–drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process. Drug Metabolism and Disposition 2007; 35(7)1232–1238
   PubMedGoogle Scholar
• Welker HA, Wiltshire H, Bullingham R. Clinical pharmacokinetics of mibefradil. Clinical Pharmacokinetics 1998; 35(6)405–423
   PubMed Web of Science ®Google Scholar
• Wiltshire HR, Sutton BM, Heeps G, Betty AM, Angus DW, Harris SR, Worth E, Welker HA. Metabolism of the calcium antagonist, mibefradil (POSICOR, Ro 40-5967). Part III. Comparative pharmacokinetics of mibefradil and its major metabolites in rat, marmoset, cynomolgus monkey and man. Xenobiotica 1997; 27(6)557–571
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Suzuki A, Kohno Y. High-throughput screening for the assessment of time-dependent inhibitions of new drug candidates on recombinant CYP2D6 and CYP3A4 using a single concentration method. Xenobiotica 2004; 34(1)87–101
   PubMed Web of Science ®Google Scholar
• Yan Z, Rafferty B, Caldwell GW, Masucci JA. Rapidly distinguishing reversible and irreversible CYP450 inhibitors by using fluorometric kinetic analyses. European Journal of Drug Metabolism and Pharmacokinetics 2002; 27(4)281–287
   PubMed Web of Science ®Google Scholar
• Yeo HR, Yeo WW. Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. British Journal of Clinical Pharmacology 2001; 51(5)461–470
   PubMed Web of Science ®Google Scholar
• Yuasa H, Numata W, Ozeki S, Watanabe J. Effect of dosing volume on gastrointestinal absorption in rats: analysis of the gastrointestinal disposition of L-glucose and estimation of in vivo intestinal membrane permeability. Journal of Pharmaceutical Sciences 1995; 84(4)476–481
   PubMedGoogle Scholar